PUBLISHER: KBV Research | PRODUCT CODE: 1093187
PUBLISHER: KBV Research | PRODUCT CODE: 1093187
LAMEA Antibody Drug Conjugates Market Size, Share & Industry Trends Analysis Report By Application (Breast Cancer, Blood Cancer, Urothelial Cancer & Bladder Cancer, and Others), By Technology, By Country and Growth Forecast, 2022 - 2028
The Latin America, Middle East and Africa Antibody Drug Conjugates Market would witness market growth of 16.9% CAGR during the forecast period (2022-2028).
Antibody-drug conjugates are a novel therapeutic class that has piqued the interest of both large & small pharmaceutical companies. The cytotoxic medication's potency in an antibody-drug combination is 100-1000 times that of the cytotoxic drug acting alone. Despite the fact that this technology is present in the majority of multinational pharmaceutical corporations, only a few companies have the capability to develop ADC.
ADCs (antibody-drug conjugates) are complicated targeted medicines made up of a cytotoxic chemical attached to an antibody scaffold. The ADC is internalized by the tumor cell and processed by the endo-lysosomal pathway after interacting with the cell surface antigen recognized by the particular antibody. The linker between the payload and the antibody is subsequently severed, and the payload is released into the cytoplasm, where it uses its cytotoxic pathway to cause cell death. ADCs can also cause tumor cell death by the so-called bystander effect, which happens when the cytotoxic warhead diffuses throughout the cell membrane to neighboring cells, causing them to apoptosis.
The regional government is putting genuine efforts to strengthen the healthcare infrastructure and cure more cancer patients. The Brazzaville Declaration on Non-communicable Disease Prevention and Control in the WHO African Region, established in 2011, reiterated African countries' recognition of non-communicable diseases (NCDs), such as cancer, as a significant health threat. The signatories agreed, among other things, to create prevention efforts, fortify the health systems to lighten the stress of NCDs, raise funds to combat the diseases, and make the national health information systems more efficient in producing information on NCDs and their risk factors. Although, progress in this direction is still slow. Only 17 of the 46 countries in the African region that replied to a WHO survey in 2010 had strategies, operational cancer policies, or strategic plans. For instance, in 2018, the count was 752,000 new cancer cases (4 percent of the overall total) & 506,000 cancer deaths in Sub-Saharan Africa.
The Brazil market dominated the LAMEA Antibody Drug Conjugates Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $206.2 Million by 2028. The Argentina market is poised to grow at a CAGR of 17.5% during (2022 - 2028). Additionally, The UAE market would display a CAGR of 16.6% during (2022 - 2028).
Based on Application, the market is segmented into Breast Cancer, Blood Cancer, Urothelial Cancer & Bladder Cancer, and Others. Based on Technology, the market is segmented into Cleavable Linker, Non-Cleavable Linker, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., AstraZeneca PLC, GlaxoSmithKline PLC, Pfizer, Inc., Astellas Pharma, Inc., Gilead Sciences, Inc., Seagen, Inc., ADC Therapeutics SA, and Daiichi Sankyo Company, Limited.
Scope of the Study
Market Segments covered in the Report:
By Application
- Breast Cancer
- Blood Cancer
- Urothelial Cancer & Bladder Cancer
- Others
By Technology
- Cleavable Linker
- Non-Cleavable Linker
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Companies Profiled
- Takeda Pharmaceutical Company Limited
- F. Hoffmann-La Roche Ltd.
- AstraZeneca PLC
- GlaxoSmithKline PLC
- Pfizer, Inc.
- Astellas Pharma, Inc.
- Gilead Sciences, Inc.
- Seagen, Inc.
- ADC Therapeutics SA
- Daiichi Sankyo Company, Limited
Unique Offerings from KBV Research
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
- 1.4.1 LAMEA Antibody Drug Conjugates Market, by Application
- 1.4.2 LAMEA Antibody Drug Conjugates Market, by Technology
- 1.4.3 LAMEA Antibody Drug Conjugates Market, by Country
- 1.5 Methodology for the research
Chapter 2. Market Overview
- 2.1 Introduction
- 2.1.1 Overview
- 2.1.1.1 Market Composition and Scenario
- 2.1.1 Overview
- 2.2 Key Factors Impacting the Market
- 2.2.1 Market Drivers
- 2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
- 3.1 KBV Cardinal Matrix
- 3.2 Recent Industry Wide Strategic Developments
- 3.2.1 Partnerships, Collaborations and Agreements
- 3.2.2 Acquisition & mergers
- 3.2.3 Approvals and Trials
- 3.3 Top Winning Strategies
- 3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
- 3.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements : 2018, May - 2022, Mar) Leading Players
Chapter 4. LAMEA Antibody Drug Conjugates Market by Application
- 4.1 LAMEA Breast Cancer Market by Country
- 4.2 LAMEA Blood Cancer Market by Country
- 4.3 LAMEA Urothelial Cancer & Bladder Cancer Market by Country
- 4.4 LAMEA Others Market by Country
Chapter 5. LAMEA Antibody Drug Conjugates Market by Technology
- 5.1 LAMEA Cleavable Linker Market by Country
- 5.2 LAMEA Non-Cleavable Linker Market by Country
- 5.3 LAMEA Others Market by Country
Chapter 6. LAMEA Antibody Drug Conjugates Market by Country
- 6.1 Brazil Antibody Drug Conjugates Market
- 6.1.1 Brazil Antibody Drug Conjugates Market by Application
- 6.1.2 Brazil Antibody Drug Conjugates Market by Technology
- 6.2 Argentina Antibody Drug Conjugates Market
- 6.2.1 Argentina Antibody Drug Conjugates Market by Application
- 6.2.2 Argentina Antibody Drug Conjugates Market by Technology
- 6.3 UAE Antibody Drug Conjugates Market
- 6.3.1 UAE Antibody Drug Conjugates Market by Application
- 6.3.2 UAE Antibody Drug Conjugates Market by Technology
- 6.4 Saudi Arabia Antibody Drug Conjugates Market
- 6.4.1 Saudi Arabia Antibody Drug Conjugates Market by Application
- 6.4.2 Saudi Arabia Antibody Drug Conjugates Market by Technology
- 6.5 South Africa Antibody Drug Conjugates Market
- 6.5.1 South Africa Antibody Drug Conjugates Market by Application
- 6.5.2 South Africa Antibody Drug Conjugates Market by Technology
- 6.6 Nigeria Antibody Drug Conjugates Market
- 6.6.1 Nigeria Antibody Drug Conjugates Market by Application
- 6.6.2 Nigeria Antibody Drug Conjugates Market by Technology
- 6.7 Rest of LAMEA Antibody Drug Conjugates Market
- 6.7.1 Rest of LAMEA Antibody Drug Conjugates Market by Application
- 6.7.2 Rest of LAMEA Antibody Drug Conjugates Market by Technology
Chapter 7. Company Profiles
- 7.1 Takeda Pharmaceutical Company Limited
- 7.1.1 Company Overview
- 7.1.2 Financial Analysis
- 7.1.3 Regional Analysis
- 7.1.4 Research & Development Expense
- 7.1.1 Recent strategies and developments:
- 7.1.1.1 Partnerships, Collaborations, and Agreements:
- 7.1.1.2 Acquisitions and Mergers:
- 7.2 F. Hoffmann-La Roche Ltd.
- 7.2.1 Company Overview
- 7.2.2 Financial Analysis
- 7.2.3 Segmental and Regional Analysis
- 7.2.4 Research & Development Expense
- 7.2.5 Recent strategies and developments:
- 7.2.5.1 Partnerships, Collaborations, and Agreements:
- 7.3 AstraZeneca PLC
- 7.3.1 Company Overview
- 7.3.2 Financial Analysis
- 7.3.3 Regional Analysis
- 7.3.4 Research & Development Expenses
- 7.3.5 Recent strategies and developments:
- 7.3.5.1 Partnerships, Collaborations, and Agreements:
- 7.4 GlaxoSmithKline PLC
- 7.4.1 Company Overview
- 7.4.2 Financial Analysis
- 7.4.3 Segmental and Regional Analysis
- 7.4.4 Research & Development Expense
- 7.4.5 Recent strategies and developments:
- 7.4.5.1 Partnerships, Collaborations, and Agreements:
- 7.4.5.2 Approvals and Trials:
- 7.5 Pfizer, Inc.
- 7.5.1 Company Overview
- 7.5.2 Financial Analysis
- 7.5.3 Regional & Segmental Analysis
- 7.5.4 Research & Development Expense
- 7.5.5 Recent strategies and developments:
- 7.5.5.1 Partnerships, Collaborations and Agreements:
- 7.6 Astellas Pharma, Inc.
- 7.6.1 Company Overview
- 7.6.2 Financial Analysis
- 7.6.3 Regional Analysis
- 7.6.4 Research & Development Expense
- 7.6.5 Recent strategies and developments:
- 7.6.5.1 Partnerships, Collaborations, and Agreements:
- 7.6.5.2 Approvals and Trials:
- 7.7 Gilead Sciences, Inc.
- 7.7.1 Company overview
- 7.7.2 Financial Analysis
- 7.7.3 Research & Development Expenses
- 7.7.4 Recent strategies and developments:
- 7.7.4.1 Acquisitions and Mergers:
- 7.7.4.2 Partnerships, Collaborations and Agreements:
- 7.8 Seagen, Inc.
- 7.8.1 Company Overview
- 7.8.2 Financial Analysis
- 7.8.3 Research & Development Expenses
- 7.8.4 Recent strategies and developments:
- 7.8.4.1 Partnerships, Collaborations, and Agreements:
- 7.9 ADC Therapeutics SA
- 7.9.1 Company Overview
- 7.9.2 Financial Analysis
- 7.9.3 Research & Development Expenses
- 7.9.4 Recent strategies and developments:
- 7.9.4.1 Partnerships, Collaborations, and Agreements:
- 7.9.4.2 Approvals and Trials:
- 7.10. Daiichi Sankyo Company, Limited
- 7.10.1 Company Overview
- 7.10.2 Financial Analysis
- 7.10.3 Research & Development Expense
- 7.10.4 Recent strategies and developments:
- 7.10.4.1 Partnerships, Collaborations, and Agreements:
LIST OF TABLES
- TABLE 1 LAMEA Antibody Drug Conjugates Market, 2018 - 2021, USD Million
- TABLE 2 LAMEA Antibody Drug Conjugates Market, 2022 - 2028, USD Million
- TABLE 3 Partnerships, Collaborations and Agreements- Antibody Drug Conjugates Market
- TABLE 4 Acquisition & mergers - Antibody Drug Conjugates Market
- TABLE 5 Approvals and trials- Antibody Drug Conjugates Market
- TABLE 6 LAMEA Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
- TABLE 7 LAMEA Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
- TABLE 8 LAMEA Breast Cancer Market by Country, 2018 - 2021, USD Million
- TABLE 9 LAMEA Breast Cancer Market by Country, 2022 - 2028, USD Million
- TABLE 10 LAMEA Blood Cancer Market by Country, 2018 - 2021, USD Million
- TABLE 11 LAMEA Blood Cancer Market by Country, 2022 - 2028, USD Million
- TABLE 12 LAMEA Urothelial Cancer & Bladder Cancer Market by Country, 2018 - 2021, USD Million
- TABLE 13 LAMEA Urothelial Cancer & Bladder Cancer Market by Country, 2022 - 2028, USD Million
- TABLE 14 LAMEA Others Market by Country, 2018 - 2021, USD Million
- TABLE 15 LAMEA Others Market by Country, 2022 - 2028, USD Million
- TABLE 16 LAMEA Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
- TABLE 17 LAMEA Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
- TABLE 18 LAMEA Cleavable Linker Market by Country, 2018 - 2021, USD Million
- TABLE 19 LAMEA Cleavable Linker Market by Country, 2022 - 2028, USD Million
- TABLE 20 LAMEA Non-Cleavable Linker Market by Country, 2018 - 2021, USD Million
- TABLE 21 LAMEA Non-Cleavable Linker Market by Country, 2022 - 2028, USD Million
- TABLE 22 LAMEA Others Market by Country, 2018 - 2021, USD Million
- TABLE 23 LAMEA Others Market by Country, 2022 - 2028, USD Million
- TABLE 24 LAMEA Antibody Drug Conjugates Market by Country, 2018 - 2021, USD Million
- TABLE 25 LAMEA Antibody Drug Conjugates Market by Country, 2022 - 2028, USD Million
- TABLE 26 Brazil Antibody Drug Conjugates Market, 2018 - 2021, USD Million
- TABLE 27 Brazil Antibody Drug Conjugates Market, 2022 - 2028, USD Million
- TABLE 28 Brazil Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
- TABLE 29 Brazil Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
- TABLE 30 Brazil Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
- TABLE 31 Brazil Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
- TABLE 32 Argentina Antibody Drug Conjugates Market, 2018 - 2021, USD Million
- TABLE 33 Argentina Antibody Drug Conjugates Market, 2022 - 2028, USD Million
- TABLE 34 Argentina Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
- TABLE 35 Argentina Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
- TABLE 36 Argentina Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
- TABLE 37 Argentina Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
- TABLE 38 UAE Antibody Drug Conjugates Market, 2018 - 2021, USD Million
- TABLE 39 UAE Antibody Drug Conjugates Market, 2022 - 2028, USD Million
- TABLE 40 UAE Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
- TABLE 41 UAE Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
- TABLE 42 UAE Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
- TABLE 43 UAE Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
- TABLE 44 Saudi Arabia Antibody Drug Conjugates Market, 2018 - 2021, USD Million
- TABLE 45 Saudi Arabia Antibody Drug Conjugates Market, 2022 - 2028, USD Million
- TABLE 46 Saudi Arabia Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
- TABLE 47 Saudi Arabia Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
- TABLE 48 Saudi Arabia Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
- TABLE 49 Saudi Arabia Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
- TABLE 50 South Africa Antibody Drug Conjugates Market, 2018 - 2021, USD Million
- TABLE 51 South Africa Antibody Drug Conjugates Market, 2022 - 2028, USD Million
- TABLE 52 South Africa Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
- TABLE 53 South Africa Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
- TABLE 54 South Africa Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
- TABLE 55 South Africa Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
- TABLE 56 Nigeria Antibody Drug Conjugates Market, 2018 - 2021, USD Million
- TABLE 57 Nigeria Antibody Drug Conjugates Market, 2022 - 2028, USD Million
- TABLE 58 Nigeria Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
- TABLE 59 Nigeria Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
- TABLE 60 Nigeria Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
- TABLE 61 Nigeria Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
- TABLE 62 Rest of LAMEA Antibody Drug Conjugates Market, 2018 - 2021, USD Million
- TABLE 63 Rest of LAMEA Antibody Drug Conjugates Market, 2022 - 2028, USD Million
- TABLE 64 Rest of LAMEA Antibody Drug Conjugates Market by Application, 2018 - 2021, USD Million
- TABLE 65 Rest of LAMEA Antibody Drug Conjugates Market by Application, 2022 - 2028, USD Million
- TABLE 66 Rest of LAMEA Antibody Drug Conjugates Market by Technology, 2018 - 2021, USD Million
- TABLE 67 Rest of LAMEA Antibody Drug Conjugates Market by Technology, 2022 - 2028, USD Million
- TABLE 68 Key Information - Takeda Pharmaceutical Company Limited
- TABLE 69 KEY INFORMATION - F. HOFFMANN-LA ROCHE LTD.
- TABLE 70 KEY INFORMATION - ASTRAZENECA PLC
- TABLE 71 Key Information - GlaxoSmithKline PLC
- TABLE 72 Key Information - Pfizer, Inc.
- TABLE 73 key information - Astellas Pharma, Inc.
- TABLE 74 Key Information - Gilead Sciences, Inc.
- TABLE 75 Key Information - Seagen Inc.
- TABLE 76 Key Information - ADC Therapeutics SA
- TABLE 77 Key Information - Daiichi Sankyo Company, Limited
List of Figures
- FIG 1 Methodology for the research
- FIG 2 KBV Cardinal Matrix
- FIG 3 Key Leading Strategies: Percentage Distribution (2018-2022)
- FIG 4 Key Strategic Move: (Partnerships, Collaborations & Agreements : 2018, May - 2022, Mar) Leading Players
- FIG 5 Recent strategies and developments: Takeda Pharmaceutical Company Limited
- FIG 6 Recent strategies and developments: Gilead Sciences, Inc.
